Tech Accelerator Partners
A partnership between Schiltz Food and Farms (Sisseton, S.D.), the UND Research Foundation, and the Department of Microbiology and Immunology at UND’s School of Medicine and Health Sciences, Avianax was established to develop antibodies and vaccines for viral, infectious diseases like West Nile and the Avian Flu. In addition, Schiltz Goose Farms North and Goose R&D have been formed to develop value-added agricultural products residing in Tolna, N.D.
The idea began when Schiltz lost 30 percent of its goose flock to disease. As the largest goose producer in North America, that loss of birds meant a significant loss of revenue. Avianax, working with UNDRF scientists and Dr. Bradley’s laboratory are using goose eggs and sera from Schiltz to produce and develop antibody therapeutics and vaccines to West Nile Virus and influenzas with the hope of solidifying viable products. Those vaccines or antibodies will become business products produced by Avianax or in partnership with a big pharmaceutical or bio- tech company.
NovaDigm is developing innovative vaccines to protect patients from fungal and bacterial infections, which can be life-threatening and drug resistant. Based in North Dakota with additional research activities at LA BioMed, NovaDigm has received funding from Domain Associates, a leading health care venture capital firm, and collaborates with multiple government agencies.
NovaDigm’s efforts are focused on development of our lead Candida- Staphylococcal vaccine, NDV-3, which is scheduled to begin Phase I clinical studies in 2010. The Company intends to bring this vaccine into clinical development and seek partners for manufacturing and commercialization. NovaDigm is assessing additional bacterial and fungal vaccine antigens to expand its product candidate pipeline.